Storia in 5 fonti

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July 29.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo7 h fa

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor stock falls 61% as FDA challenges Deramiocel efficacy; Phase 3 DMD trial missed primary endpoint, cardiac data show no benefit. Signal for biotech acquirers: late-stage efficacy gaps elevate regulatory risk, erode valuations, tighten clinical M&A discipline.

originale

Timeline cronologica

lunedì 27 luglio 2026·biopharmadive.com
FDA scientists question Capricor data; Legend CEO steps down
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca…
lunedì 27 luglio 2026·statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Confronto fonti

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Timeline cronologica

FDA scientists question Capricor data; Legend CEO steps down

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA…

FDA scientists question Capricor data; Legend CEO steps down

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…